Reggie the Red Blood Cell
Join Reggie, our curious red blood cell, on a journey exploring connections between the heart, kidneys and pancreas. Click here to read more!
Search
BI India joins forces with PPAM and BMC to Stop Rabies
This initiative will adopt a two-pronged approach of vaccination and education.
Boehringer Ingelheim allocates COVID relief fund to support underserved communities and patients in India
Boehringer Ingelheim is making available a Euro One Million COVID relief fund to support underserved communities and patients in India. Learn more here.
Boehringer Ingelheim India recognized as Top Employer 2024
Boehringer Ingelheim India recognized as Top Employer 2024
Global Code of Conduct
Our Code of Conduct demonstrates for each and every one that integrity is “part of our DNA”. Click here to learn more about our Code of Conduct.
Purchasing
Find out information about Boehringer Ingelheim's purchasing and supplier relationships here, as well as links to useful resources for suppliers too.
Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug
Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug.
Looking behind the scenes of Afrika Kommt!
Since inception in 2008, Afrika Kommt! has upskilled over 156 young professionals from Sub-Saharan Africa. Learn more about this programme here.
1885-1948
In 1885, Albert Boehringer purchased a small tartar factory in the Rhine-Hessian village of Nieder-Ingelheim. Click here to learn more about our history.
Boehringer Ingelheim India’s stroke awareness campaign enters the GUINNESS WORLD RECORDS™
Boehringer Ingelheim India’s stroke awareness campaign enters the GUINNESS WORLD RECORDS™. Click here to read the press release and find out more.
More Green
Our MORE GREEN pillar encompasses environmental initiatives that consider many different aspects. Click here to learn more about our MORE GREEN pillar.
1988-2015
Following the death of Hubertus Liebrecht (1991), the owning family made some fundamental decisions regarding the company’s alignment. Learn more here.
Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India
Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India. Click here to find out and learn more.
Boehringer Ingelheim and IIT Kanpur join hands for social impact
Boehringer Ingelheim India to support Lenek Technologies, a startup incubated at SIIC, IIT Kanpur to improve tuberculosis screening through its innovative handheld X-ray device.
COVID-19 Joining forces against COVID-19
While the challenges posed by the COVID-19 pandemic are massive, so are the good examples of corporate citizenship arising all over the world. Learn more.
COVID-19 Boehringer Ingelheim Singapore charity donations
Find out how Boehringer Ingelheim Singapore is offering support for healthcare workers and vulnerable communities. Click here to learn more.
1948-1988
Following the death of Albert Boehringer (1861-1939), his two sons and his son-in-law Julius Liebrecht took over this family company. Learn more.
Solidarity with Ukraine
Our company condemns the military aggression against Ukraine and is committed to helping those in need in the longer term. Click here to learn more.
COVID-19 Learning from the pandemic
Online training options develop vets and other animal health professionals’ skills helping them overcome movement restrictions to thrive around the globe.
Jardiance® (empagliflozin) now approved in India for treatment of chronic kidney disease
Jardiance® (empagliflozin) now approved in India
COVID-19 Global Access Commitment with Gates Foundation
Boehringer Ingelheim commits to provide global access to COVID-19 therapeutics by signing a communiqué with the Bill & Melinda Gates Foundation.
UK donates to vulnerable children and local emergency fund
Find out how colleagues in the UK are helping disadvantaged young people in isolation, and supporting charities in the community. Click here to learn more.
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalization for heart-failure and cardiovascular death
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalisation for heart-failure and cardiovascular death. Find out more here.
Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine
Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine. Click here to find out and learn more information.
Dr. V. Mohan Releases 9-point Action for People with Diabetes
Dr V. Mohan has released a 9-point action plan to ensure health for people with diabetes. Click here to read the press release and find out more.